EssilorLuxottica Société anonyme (ENXTPA:EL) is back in focus after expanding its collaboration with Meta through the launch of Meta Glasses, a new AI eyewear collection targeting mass market adoption.

See our latest analysis for EssilorLuxottica Société anonyme.

For context, EssilorLuxottica Société anonyme's share price has softened recently, with a 30 day share price return down 6.34% and a 90 day share price return down 15.42%, while the 1 year total shareholder return is down 28.51%. As a result, the Meta Glasses launch arrives at a time when sentiment has been weak and investors are reassessing both growth potential and risk.

If the Meta partnership has you thinking about where AI hardware could go next, it might be worth scanning the market for other opportunities in this space through our 51 AI infrastructure stocks

So with EssilorLuxottica Société anonyme’s share price under pressure yet some tools pointing to a discount, should you see the recent pullback as a genuine buying opportunity, or is the market already pricing in future growth?

Most Popular Narrative: 25% Undervalued

EssilorLuxottica Société anonyme’s most followed valuation narrative points to a fair value of €218.59 versus the last close of €164.05. This frames the current weakness as a sizeable discount that hinges heavily on how its smart eyewear and MedTech ambitions play out.

Expansion into medical technologies, AI-driven healthcare platforms, and vertically integrated MedTech services increases operational complexity and ongoing SG&A costs, creating execution risk and the likelihood of cost overruns that could depress EBITDA and overall profitability over time.

Read the complete narrative.

Want to see what keeps that valuation elevated despite these cost concerns? The narrative leans on specific growth, margin and earnings projections that could reset expectations if they play out differently.

Result: Fair Value of €218.59 (UNDERVALUED)

Have a read of the narrative in full and understand what's behind the forecasts.

However, EssilorLuxottica Société anonyme’s smart eyewear story could look very different if legal disputes around patents widen or if regulatory scrutiny on MedTech and data use intensifies.

Find out about the key risks to this EssilorLuxottica Société anonyme narrative.

Another View: EssilorLuxottica Société anonyme Through the Lens of Market Multiples

The fair value of €218.59 suggests EssilorLuxottica Société anonyme is undervalued, but the market is telling a different story. At a P/E of 32.6x, the stock trades slightly above peers at 32.4x and well above the European Medical Equipment average of 25x, while the fair ratio is 26.9x.

That gap implies investors are already paying a premium compared with both sector and fair ratio benchmarks, which could limit upside if sentiment weakens or execution stumbles. With such a rich earnings multiple against a model that flags only a 2/6 value score, how comfortable are you with paying up for this story?

See what the numbers say about this price — find out in our valuation breakdown.

Next Steps

If the mixed signals around EssilorLuxottica Société anonyme leave you unsure, treat that as a prompt to look more closely and act promptly while sentiment is still resetting. Balance your own view of the upside against the potential downsides by weighing the 2 key rewards and 1 important warning sign

Looking for more investment ideas beyond EssilorLuxottica Société anonyme?

Do not stop with EssilorLuxottica Société anonyme. Broaden your watchlist now so you are not relying on a single stock when fresh opportunities are already on the table.

• Target stronger value by scanning companies that combine quality and attractive pricing using our 190 high quality undervalued stocks
• Strengthen your income stream by reviewing stocks that offer reliable payouts with our 483 dividend fortresses
• Prioritise resilience by focusing on companies flagged for sturdier fundamentals through the 290 resilient stocks with low risk scores

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.